Skip NavigationSkip to Content
Return Return to Search Results

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia

  1. Author:
    Kim, Miriam Y
    Yu, Kyung-Rok
    Kenderian, Saad S
    Ruella, Marco
    Chen, Shirley
    Shin, Tae-Hoon
    Aljanahi, Aisha A
    Schreeder, Daniel
    Klichinsky, Michael
    Shestova, Olga
    Kozlowski, Miroslaw S
    Cummins, Katherine D
    Shan, Xinhe
    Shestov, Maksim
    Bagg, Adam
    Morrissette, Jennifer J D
    Sekhri, Palak
    Lazzarotto, Cicera R
    Calvo, Katherine R
    Kuhns, Doug
    Donahue, Robert E
    Behbehani, Gregory K
    Tsai, Shengdar Q
    Dunbar, Cynthia E
    Gill, Saar

  2. Author Address

    Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA., Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA., Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA., Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA; Department of Chemistry and Molecular & Cellular Biology, Georgetown University, Washington, D.C. 20057, USA., Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA., Genomics and Computational Biology Graduate Group, University of Pennsylvania, Philadelphia, PA 19104, USA., Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA., The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA., Department of Hematology, St. Jude Children 39;s Research Hospital, Memphis, TN 38105, USA., Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA., Clinical Services Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA; Division of Hematology, Department of Medicine, Ohio State University, Columbus, OH 43210, USA., Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: dunbarc@nhlbi.nih.gov., Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. Electronic address: saargill@pennmedicine.upenn.edu.,
    1. Year: 2018
    2. Date: May 31
    3. Epub Date: 2018 05 31
  2. Journal: Cell
    1. 173
    2. 6
    3. Pages: 1439-1453.e19
  4. Type of Article: Article
  5. ISSN: 0092-8674
  1. Abstract:

    The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPCs), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPCs and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity. Copyright © 2018 Elsevier Inc. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.cell.2018.05.013
  3. PMID: 29856956
  4. View record in Web of Science®
  5. WOS: 000433989100016
  6. PII : S0092-8674(18)30590-7

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel